Evidence map›Paper›PMID 39557851›Full record

ArticleCell death & disease2024

RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2α pathways.

Ke-Jie Wang, Sha-Zhou Ye, Xiao-Long Jia, Kai-Yun Wang, Xiang-Yu Meng, Xin Fei, Shi-Jie Ye, Qi Ma

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ke-Jie WangTranslational Research Laboratory for Urological Diseases, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.
Sha-Zhou YeTranslational Research Laboratory for Urological Diseases, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.
Xiao-Long JiaDepartment of Urology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.
Kai-Yun WangDepartment of Urology, the Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, P.R. China.
Xiang-Yu MengTranslational Research Laboratory for Urological Diseases, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.
Xin FeiHealth Science Center, Ningbo University, Ningbo, Zhejiang, P.R. China.
Shi-Jie YeHealth Science Center, Ningbo University, Ningbo, Zhejiang, P.R. China.
Qi MaComprehensive Genitourinary Cancer Center, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China. fyymaqi@nbu.edu.cn.ORCID 0000-0002-5350-0362

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81272828Natural Science Foundation of Ningbo (Ningbo Natural Science Foundation) 2023J158
6 · The paper itself

Abstract

The RON receptor tyrosine kinase is critical in the pathogenesis of various cancer types, however, its role in bladder cancer invasive growth is still largely unknown. Here, we found that over 90% of bladder cancer samples exhibit elevated levels of RON expression, with significantly higher expression levels observed in invasive bladder cancer compared to non-invasive bladder cancer. In vitro, RON activation resulted in increased bladder cancer cell migration and invasiveness. Results from mRNA sequencing and transcriptome analysis further demonstrated that MMP12, a downstream molecule of RON, is functionally involved in regulating RON-mediated bladder cancer cell migration and invasiveness. The underlying mechanism appeared to be the RON-mediated inhibition of HIF-2α ubiquitination, which is channeled through the activation of the JNK signaling pathway. Consequently, the activated JNK pathway increased MMP12 expression, ultimately driving bladder cancer cell migration and invasion. As evident in bioinformatics and dual-luciferase reporter assays, the RON mRNA at its 3'-untranslated regions specifically interacted with hsa-miR-659-3p. The binding of hsa-miR-659-3p downregulated the RON gene expression, attenuating the receptor-mediated tumorigenic activities of bladder cancer cells in vitro and in vivo. In conclusion, aberrant RON expression in bladder cancer cells and MMP12 and HIF-2α activities form a functional axis that causes increased bladder cancer cell migration and invasion. The fact that hsa-miR-659-3p downregulates RON expression indicates its critical role in attenuating RON-mediated tumorigenic effect on bladder cancer cells. These findings highlight the importance of RON targeting as a therapeutic means for potential bladder cancer therapy.

Indexed as

Basic Helix-Loop-Helix ProteinsCell MovementGene Expression Regulation, NeoplasticMatrix Metalloproteinase 12Receptor Protein-Tyrosine KinasesUrinary Bladder NeoplasmsAnimalsCarcinogenesisCell Line, TumorEndothelial PAS Domain-Containing Protein 1HumansMaleMiceMice, NudeMicroRNAsNeoplasm InvasivenessBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Matrix Metalloproteinase 12MicroRNAsReceptor Protein-Tyrosine KinasesRON protein

Identifiers

PMID39557851
PMCPMC11574271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.